Oliver Bautista

7.2k total citations
34 papers, 1.8k citations indexed

About

Oliver Bautista is a scholar working on Epidemiology, Surgery and Immunology. According to data from OpenAlex, Oliver Bautista has authored 34 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Epidemiology, 9 papers in Surgery and 7 papers in Immunology. Recurrent topics in Oliver Bautista's work include Cervical Cancer and HPV Research (22 papers), Hepatitis B Virus Studies (21 papers) and Genital Health and Disease (9 papers). Oliver Bautista is often cited by papers focused on Cervical Cancer and HPV Research (22 papers), Hepatitis B Virus Studies (21 papers) and Genital Health and Disease (9 papers). Oliver Bautista collaborates with scholars based in United States, Canada and Colombia. Oliver Bautista's co-authors include Kevin A. Ault, Eliav Barr, Scott Vuocolo, Cosette M. Wheeler, Alfred J. Saah, Richard M. Haupt, Evan R. Myers, Janine T. Bryan, Joseph Monsonégo and Joaquín Luna and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PEDIATRICS.

In The Last Decade

Oliver Bautista

32 papers receiving 1.7k citations

Peers

Countries citing papers authored by Oliver Bautista

Since Specialization

Citations

This map shows the geographic impact of Oliver Bautista's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Bautista with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Bautista more than expected).

Fields of papers citing papers by Oliver Bautista

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Bautista. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Bautista. The network helps show where Oliver Bautista may publish in the future.

Co-authorship network of co-authors of Oliver Bautista

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Bautista. A scholar is included among the top collaborators of Oliver Bautista based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Bautista. Oliver Bautista is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of Prior 9-Valent Human Papillomavirus Vaccination on Subsequent Lower Genital Tract Dysplasia After Cervical Excisional Surgery 2025 ·Obstetrics and Gynecology ·Elmar A. Joura, Susanne K. Kjær, Oliver Bautista, Alain Luxembourg, Alfred J. Saah, Anna R. Giuliano	0
2	Long-term effectiveness of the nine-valent human papillomavirus vaccine: Interim results after 12 years of follow-up in Scandinavian women 2024 ·Human Vaccines & Immunotherapeutics ·Susanne K. Kjær, (unknown), Karin Sundström, Christian Munk, (unknown), Oliver Bautista, (unknown), Sonali Rawat, Alain Luxembourg	7
3	Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial 2023 ·The Lancet Infectious Diseases ·Rituparna Das, Daniel Blázquez‐Gamero, David I. Bernstein, Soren Gantt, Oliver Bautista, Karen Beck, (unknown), Daniel I. S. Rosenbloom, Dai Wang, Michael Ritter, Beth Arnold, Paula W. Annunziato, Kevin L. Russell	26
4	Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men 2021 ·Contemporary Clinical Trials ·Anna R. Giuliano, Timothy Wilkin, Oliver Bautista, (unknown), (unknown), Sheri Dubey, Alain Luxembourg, Sonali Rawat, (unknown), Christine Velicer, (unknown), (unknown)	23
5	Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals 2021 ·Contemporary Clinical Trials ·Hedy Teppler, Oliver Bautista, (unknown), Jennifer McCauley, Alain Luxembourg	4
6	Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up 2020 ·Papillomavirus Research ·(unknown), Jaime Alberto Restrepo, Julio C. Reina, Punnee Pitisuttithum, Àngels Ulied, Meera Varman, Pierre Van Damme, Edson Duarte Moreira, Daron Ferris, S. Block, Oliver Bautista, Nancy Gallagher, Jennifer McCauley, Alain Luxembourg	37
7	Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population 2019 ·Gynecologic Oncology ·Anna R. Giuliano, Elmar A. Joura, Suzanne M. Garland, Warner K. Huh, Ole-Erik Iversen, Susanne K. Kjær, Alex Ferenczy, Robert J. Kurman, Brigitte M. Ronnett, Mark H. Stoler, Oliver Bautista, Erin Moeller, Michael Ritter, Christine Shields, Alain Luxembourg	63
8	Intention-to-prevent analyses for estimating human papillomavirus vaccine efficacy in clinical studies 2017 ·Contemporary Clinical Trials Communications ·Alfred J. Saah, Oliver Bautista, Alain Luxembourg, Gonzalo Pérez	2
9	Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine 2015 ·Vaccine ·Suzanne M. Garland, Tak‐Hong Cheung, (unknown), Lone Kjeld Petersen, Josefina Romaguera, (unknown), Oliver Bautista, Christine Shields, Scott Vuocolo, Alain Luxembourg	62
10	Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine 2015 ·Contemporary Clinical Trials ·Alain Luxembourg, Oliver Bautista, Erin Moeller, Michael Ritter, Joshua Chen	16
11	End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age 2011 ·British Journal of Cancer ·Xavier Castellsagué, Núbia Muñóz, Punnee Pitisuttithum, Daron Ferris, Joseph Monsonégo, Kevin A. Ault, Joaquín Luna, Evan R. Myers, (unknown), Oliver Bautista, Janine T. Bryan, Scott Vuocolo, Richard M. Haupt, Alfred J. Saah	260
12	Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial 2009 ·The Lancet ·Nubia Muñóz, (unknown), Punee Pitisuttithum, Damrong Tresukosol, Joseph Monsonégo, Kevin A. Ault, Christine Clavel, Joaquín Luna, Evan R. Myers, (unknown), Oliver Bautista, Janine T. Bryan, Frank J. Taddeo, Mark T. Esser, Scott Vuocolo, Richard M. Haupt, Eliav Barr, Alfred J. Saah	362
13	Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women 2008 ·American Journal of Obstetrics and Gynecology ·Eliav Barr, Christine K. Gause, Oliver Bautista, Radha Railkar, Lisa Lupinacci, Ralph P. Insinga, Heather L. Sings, Richard M. Haupt	25
14	Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia 2006 ·Obstetrical & Gynecological Survey ·Constance Mao, Laura A. Koutsky, Kevin A. Ault, Cosette M. Wheeler, Darron R. Brown, Dorothy J. Wiley, Frances B. Alvarez, Oliver Bautista, Kathrin U. Jansen, Eliav Barr	21
15	Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia 2006 ·Obstetrics and Gynecology ·Constance Mao, Laura A. Koutsky, Kevin A. Ault, Cosette M. Wheeler, Darron R. Brown, Dorothy J. Wiley, Frances B. Alvarez, Oliver Bautista, Kathrin U. Jansen, Eliav Barr	338
16	Baseline Factors as Predictors of Clinical Progression of Benign Prostatic Hyperplasia in Men Treated With Placebo 2006 ·The Journal of Urology ·E. David Crawford, Shandra Wilson, John D. McConnell, Kevin M. Slawin, (unknown), Joseph A. Smith, Alan G. Meehan, Oliver Bautista, (unknown), John W. Kusek, Leroy M. Nyberg, Claus G. Roehrborn	184
17	Group sequential large sample T²‐like χ² tests for multivariate observations 2003 ·Statistics in Medicine ·John M. Lachin, Samuel W. Greenhouse, Oliver Bautista	0
18	Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial 2003 ·Controlled Clinical Trials ·Oliver Bautista, John W. Kusek, Leroy M. Nyberg, John D. McConnell, Raymond P. Bain, Gary J. Miller, E. David Crawford, Steven A. Kaplan, Stephen A. Sihelnik, Michael K. Brawer, (unknown)	81
19	A Flexible Stochastic Curtailing Procedure for the Log-Rank Test 2000 ·Controlled Clinical Trials ·Oliver Bautista, Raymond P. Bain, John M. Lachin	4
20	Stratified-adjusted versus unstratified assessment of sample size and power for analyses of proportions 1995 ·Cancer treatment and research ·John M. Lachin, Oliver Bautista	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact